A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Sponsor: Daiichi Sankyo
Terminated
The study is being terminated for lack of efficacy.
Other terminated trials from Daiichi Sankyo
Other Sickle Cell Disease trials with similar outcome
This PHASE3 trial investigates Sickle Cell Disease and is currently terminated or withdrawn. Daiichi Sankyo leads this study, which shows 11 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Mar 2024 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Oct 2019 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Oct 2019 [monthly]
Terminated PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .